Zhitong Financial App News, Haixi New Pharmaceutical (02637.HK) issued an announcement. The drug candidate HXP056 drug candidate HXP056, was granted Fast Track Designation (“FTD”) by the US Food and Drug Administration (U.S. Food and Drug Administration, “FDA”) to develop treatments for neovascular age-related macular degeneration (nephrogenesis) agerelated macular degeneration (“NaMD”, also known as wet age-related macular degeneration, “wAMd”). Being granted FTD certification this time will help the company to develop closer communication with the FDA on the clinical development of HX9428 and advance its global clinical development process.

Zhitong Financial App News, Haixi New Pharmaceutical (02637.HK) issued an announcement. The drug candidate HXP056 drug candidate HXP056, was granted Fast Track Designation (“FTD”) by the US Food and Drug Administration (U.S. Food and Drug Administration, “FDA”) to develop treatments for neovascular age-related macular degeneration (nephrogenesis) agerelated macular degeneration (“NaMD”, also known as wet age-related macular degeneration, “wAMd”). Being granted FTD certification this time will help the company to develop closer communication with the FDA on the clinical development of HX9428 and advance its global clinical development process.